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Tumor progression is affected not only by factors that are intrinsic
to the tumor cells themselves, but also by extrinsic factors in the
tumor microenvironment. While the importance of oncogenes and
other tumor cell-autonomous factors should not be underestimated,
the effects of stromal factors can be surprisingly strong in determining
the ability of a tumor to thrive. This has been especially well-
documented in the case of breast and ovarian cancer (Roskelley and
Bissell, 2002), but also applies to other types of neoplasms. For
example, tumorigenesis in the central nervous system is also highly
dependent on stromal factors (Rubin, 2009). In addition to contribu-
tions from vascular (Plate and Risau, 1995; Fischer et al., 2005) and
extracellular matrix elements (Yuan et al., 2007; Delamarre et al.,
2009), brain tumor progression can be affected by neural-speciﬁc
stromal elements such as astrocytes (Couldwell et al., 1992; van der
Valk et al., 1997; Duntsch et al., 2005), oligodendrocyte progenitors
(Assanah et al., 2006; Ivkovic et al., 2008), and even neural stem cells
(Glass et al., 2005; Duntsch et al., 2005).Perhaps the most universal example of an essential stromal
element is the tumor vasculature. Due to the need for gas exchange
and access to nutrients, tumor vascularization is required in order for
the neoplasm to expand beyond a very small size (Folkman, 1995;
Hanahan and Folkman, 1996). The successful recruitment of tumor
vasculature is often referred to as the angiogenic switch, the point at
which hyperplastic foci acquire the ability to develop into full-blown
neoplasms (Folkman et al., 1989; Hanahan and Folkman, 1996;
Bergers and Benjamin, 2003; Lin et al., 2006). The ability of an
incipient tumor to recruit new blood vessels is critical for its ability
not only to grow in size, but also to metastasize to distant sites using
blood vessels and lymphatics as conduits. Vascular hyperplasia,
involving aggressive recruitment of pericytes and endothelial cells,
is a particularly strong characteristic of brain tumors (Assanah et al.,
2006; Shibuya, 2009).
The NG2 proteoglycan is a cell surface molecule that has the
potential to affect tumor progression both as a tumor cell-autonomous
entity and as a component of the tumor vasculature (Stallcup and
Huang, 2008). NG2 is commonly found in several types of tumors,
notably gliomas (Schrappe et al., 1991; Chekenya and Pilkington,
2002; Shoshan et al., 1999) and melanomas (Campoli et al., 2004;
Maciag et al., 2008), and can promote tumor cell proliferation,motility,
and resistance to apoptosis (Burg et al, 1997; 1998;Makagiansar et al.,
2004; 2007; Chekenya et al., 2008). The proteoglycan is also a
prominent component of pericytes in the microvasculature, including
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pericyte/endothelial cell interaction (Ozerdem et al., 2001; 2002;
Chekenya et al., 2002; Ozerdem and Stallcup, 2003; 2004; Fukushi
et al., 2004; Brekke et al., 2006; Tigges et al., 2008).
In order to dissect the respective roles of tumor cell NG2 versus
pericyte NG2 in tumor progression, it is necessary to set up
experimental systems in which NG2 is expressed only in the host or
only in the tumor cells. Both types of analyses are possible using
comparisons of wild type and NG2 null mice (Grako et al., 1999;
Ozerdem and Stallcup, 2004; Kadoya et al., 2008; Kucharova and
Stallcup, 2010) in conjunction with tumor cell lines that are positive
or negative for NG2 (Burg et al., 1997; 1998). In this study, we have
examined tumors derived by implantation of the NG2-negative
melanoma cell line B16F10 (Fidler, 1973), NG2-transfected B16F10
cells (Burg et al., 1998), and the NG2-positive astrocytoma cell line
CT2A (Seyfried et al., 2008) in the subcortical white matter of C57Bl/6
wild type and NG2 null mice. Tumors derived from NG2-negative
B16F10 cells have been of particular value in the current work, since
they allow us to evaluate the tumor promoting effects of stromal NG2
without interference from the effects of tumor cell NG2. Thismelanoma
cell line is a highly relevant model for characterizing tumor growth in
the brain, because metastasis to the brain is a frequent occurrence in
melanomaprogression (Sloanet al., 2009;Guzel et al., 2009).Our results
show that NG2 expression by microvascular pericytes is a key factor in
the development of a functional vasculature that can support aggressive
expansion of tumors growing in the brain. Our results are relevant to
normal development, as well, since pericyte/ endothelial cell interac-
tions are also critical for the development and function of microvessels
in normal tissues.
Materials and methods
Cell lines
NG2-negative B16F10 mouse melanoma cells (American Type
Culture Collection; Fidler, 1973), NG2-transfected B16F10 cells
(B16F10/NG2; Burg et al., 1998), and NG2-positive CT2A mouse
astrocytoma cells (Seyfried et al, 2008) weremaintained in Dulbecco's
Modiﬁed Eagle's Medium (DMEM) containing 10% fetal calf serum,
2 mM glutamine, 100 IU/ml penicillin, and 100 μg/ml streptomycin
sulfate. All cells are of C57Bl/6 origin.
Animals
Wild type C57Bl/6 mice, C57Bl/6 NG2 null mice (Grako et al.,
1999; Ozerdem and Stallcup, 2004), and C57Bl/6 collagen VI null mice
(Bonaldo et al., 1998) were maintained in the Sanford-Burnham
Vivarium (fully accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care). All animal procedures were
performed in accordance with Ofﬁce of Laboratory Animal Welfare
regulations and were approved by Sanford-Burnham Institutional
Animal Care and Use Committee review prior to execution.
Cell microinjection and growth of tumors
B16F10, B16F10/NG2, and CT2A cells were harvested by trypsi-
nization and re-suspended in DMEM at a density of 5×106 cells/ml.
From this suspension, 2 μl (104 cells) were microinjected into the
forcep minor of the corpus callosum (stereotactic coordinates
relative to bregma: 2 mm lateral, 1 mm rostral, 2 mm deep) of
male wild type, NG2 null, and collagen VI null mice under Avertin
anesthesia. Mice from the three lines were of similar ages and
weights (13–15 weeks and 28–32 g). An injection rate of 0.2 μl/min
wasmaintained by using a Stoeltingmicropump connected to a 10-μl
Hamilton syringe with a 26 gauge needle. Animals were monitored
daily for signs of distress, such asweight loss, seizures, posturing, andnasal and/or periorbital hemorrhage. However, these symptoms
were never observed during our study. At 3, 5, 7, 11, and 17 days
post-injection of B16F10 cells, animals under Avertin anesthesia
were perfused with 4% paraformaldehyde, and the brains were
removed for analysis. B16F10/NG2 tumors were examined at
11 days post-injection, while CT2A tumors were analyzed at
26 days after injection. Exceptions to this euthanasia regimen were
cases in which mice were injected with FITC-dextran, FITC-LEA
lectin, or pimonidazole, as described below.
Measurements of tumor size and weight
Brains taken from mice at 17 (B16F10), 11 (B16F10/NG2), or 26
(CT2A) days post-injection were weighed and then photographed
using an Olympus SZ2-ILST dissecting light microscope (Tokyo,
Japan). After measuring the long and short axes of the tumors, brains
were sliced through the midline of the tumor to allow measurement
of tumor depth. Tumor volumes were calculated using the formula:
V=0.52×A×B×C, where A is the length of the short axis, B that of the
long axis, and C that of tumor depth. Tumor weights (W) were
calculated using the formula: W=M−0.42 g, where M is the
measured weight of brain plus tumor and 0.42 g is the average
weight of the adult mouse brain.
At 3, 5, 7, and 11 days post-injection, B16F10 tumor volumes were
estimated after slicing the brain through the injection site to locate the
tumor midline. The pigmentation of the melanoma cells made the
tumors readily visible so that the long and short axes could be
determined. Tumor volumes were calculated as described above.
Immunohistochemistry, microscopy, and cell counting.
In a few cases, brains and tumors were embedded in parafﬁn, and
10 μm sections prepared for hematoxylin and eosin staining. In most
cases, ﬁxed brains were cryoprotected by overnight immersion in 20%
sucrose and then frozen in OCT. These blocks were used to prepare
20 μm sections on a Reichert-Jung 1800 cryostat microtome. Immuno-
ﬂuorescence analysis was performed on these sections as described
previously (Ozerdem et al., 2001) using the following antibodies: rat
anti-CD31 (1:100; BDBiosciences, CA), goat anti-mouseVEGFR2 (1:500,
R&DSystems), rabbit anti-PDGFRβ (1:100, Ozerdemet al., 2002), rabbit
anti-NG2 (1:100, Ozerdem et al., 2001), mouse anti-smooth muscle
actin (1:500; Sigma), rabbit anti-collagen IV and rabbit anti-collagen VI
(1/100, Millipore), and Cy5 or FITC-conjugated second antibodies
(1:300, Jackson ImmunoResearch, PA). Examination and image capture
(TIFF images) from immunostained sectionswere accomplished using a
BioRad (Hercules, CA) inverted Radiance 2100 Multiphoton Confocal
Microscope as described previously (Tigges et al., 2008). Serial 1 μm
optical sections across the entire 20 μm thickness of the histological
specimenswere obtained from 3 to 5 brains/tumors at each time point.
Areas (number of pixels) with immunostaining greater than a set
threshold were quantiﬁed using computer based morphometry
software (Image-Pro Plus 4.5, Diagnostic Instruments, USA).
Determination of vascular leakage
FITC-dextran (250 kDa; Sigma)was injected intravenously (100 μl of
a 50 mg/ml solution) via the tail vein into Avertin-anesthetized, tumor-
bearing mice. After 10 min to allow circulation, mice were cervically
dislocated while still under anesthesia. Whole brains with tumors were
removed without perfusion and ﬁxed overnight in 4% paraformalde-
hyde. After cryoprotection in 20% sucrose, material was frozen in
OCT compound. Cryosections (20 μm)were prepared, and the extent of
FITC-dextran leakage from blood vessels was estimated on the basis of
green ﬂuorescence located external to CD31-positive vascular struc-
tures. Using Image J software, the borders of CD31-labeled blood vessels
were identiﬁed, so that extravascular FITC-dextran could be quantiﬁed
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leakage was deﬁned as total extravascular FITC-dextran per tumor
ﬁeld.
Determination of vascular patency
Functional connection of tumor vessels to the circulation was
assessed in Avertin anesthetized mice by tail vein injection of 100 μl of
0.5 mg/ml FITC-labeled Lysopersicon esculentum agglutinin (LEA) lectin
(Vector Laboratories). After circulation for 3 min to allow binding to the
vascular endothelium, unbound lectin was cleared by perfusion with
saline, followed by perfusion with 4% paraformaldehyde for tissue
ﬁxation. Labeling of vessels with FITC-LEA lectin was compared with
immunolabeling for CD31 or VEGFR2 as a means of quantifying the
percentage of patent vessels.
Determination of tumor hypoxia
Tumor hypoxia was evaluated using a Hypoxyprobe-1 kit
(Chemicon International, Temecula, CA). Tumor-bearing mice were
injected intraperitoneally with 60 mg/kg pimonidazole hydrochlo-
ride and euthanized without perfusion after a 30-min incubation
period. Brains were ﬁxed overnight in 4% paraformaldehyde and then
cryoprotected in 20% sucrose. Brains were frozen in OCT, and 20 μm
sections were prepared. For visualization of hypoxic areas, sections
were incubated overnight with FITC-conjugated Hypoxyprobe anti-
body. Levels of hypoxia were determined by quantifying green pixels
per tumor area.
Statistical analysis
All results were expressed as mean±SE. Statistical analyses were
performed using the two-tailed t test. Pb0.05 was considered
statistically signiﬁcant.
Results
Effect of host NG2 ablation on astrocytoma and melanoma growth in
the brain
NG2-negative B16F10 melanoma cells, NG2-positive B16F10
melanoma cells (B16F10/NG2), and NG2-positive CT2A astrocytoma
cells were microinjected intracranially into the subcortical white
matter (corpus callosum) of both wild type and NG2 null mice. For the
CT2A studies, 9 wild type and 9 NG2 null recipients were euthanized
26 days after tumor cell injection. Fig. 1A shows that the average CT2A
tumor size in NG2 null mice was 7-fold smaller than the average
tumor size in wild type mice. Experiments with B16F10/NG2 cells
(7 mice in each group) were terminated at 11 days due to rapid
growth and invasion of these tumors in thewild typemice. At 11 days,
B16F10/NG2 tumors in NG2 null mice were 10-fold smaller than
tumors in wild type mice (Fig.1B). For the B16F10 studies, cohorts of
mice were euthanized at 3, 5, 7, 11, and 17 days post-injection to
allow examination of tumor progression. Even in the case of very
small early tumors, the pigmentation of the B16F10 cells makes it
straightforward to determine tumor boundaries and to quantify
tumor sizes. A plot of tumor sizes as a function of time (Fig. 1C) reveals
that tumors inwild type and NG2 null mice begin to diverge in volume
between days 3 and 7 post-injection (inset panel), and that this
difference has become quite large at 17 days post-injection. At
17 days, tumors in NG2 null mice are roughly one-third the size of
tumors in wild type mice (Fig. 1D). Thus, in the case of all three cell
lines, the NG2 negative host background is responsible for reduced
tumor progression.
In all three tumors growing in wild type mice, NG2 is expressed by
pericytes associated with CD31-positive endothelial cells in tumorblood vessels (Fig. 1E shows this for the B16F10 and B16F10/NG2
tumors). Fig. 1E also demonstrates the expression of NG2 by B16F10/
NG2 cells (also true for CT2A cells, data not shown) and the absence of
NG2 from B16F10 cells. In order to focus on the stromal role of NG2 in
tumor progression, we devoted our attention to the B16F10 tumors
for the remainder of this study. The role of tumor cell NG2 in
neoplastic progression (for example, in the case of B16F10/NG2 and
CT2A cells) will be the subject of future studies. This is clearly a topic
of interest in light of the extremely aggressive growth and invasion
seen with B16F10/NG2 tumors.Effect of host NG2 ablation on pericyte/endothelial cell interaction
Since NG2 is not expressed by the B16F10 tumor cells in our
model, stromal elements must be responsible for the effects of NG2
ablation on B16F10 tumor progression. In the context of the central
nervous system, NG2 is expressed by oligodendrocyte progenitor
cells, by macrophages/microglia, and by microvascular pericytes
(Stallcup and Huang, 2008). Leaving the former two cell types for
future investigation, we have focused our initial attention on
pericytes in the tumor vasculature. Our previous work using
pathological retinal and corneal models has demonstrated reduced
neovascularization in the NG2 null mouse (Ozerdem and Stallcup,
2004). This decrease stems largely from deﬁciencies in pericyte
recruitment and from loss of NG2-dependent pericyte interaction
with endothelial cells (Fukushi et al., 2004). To look for evidence of
changes in pericyte recruitment and/or pericyte/endothelial cell
interaction in B16F10 tumors, we collected tumor specimens at day 7
following intracranial injection. This time point offers the advantage
of providing samples that are large enough to allow preparation of
multiple histological sections, but small enough to avoid problems
with necrosis that become common at later stages. For example in
day 11 tumors, not only is necrosis a signiﬁcant factor, but many
vessels also begin to exhibit extreme dilation that makes straight-
forward analysis difﬁcult.
Using the day 7 tumor specimens from wild type and NG2 null
brains, we did not detect signiﬁcant differences in either microvas-
cular density or vessel diameter (data not shown). We also did not
ﬁnd differences in the absolute numbers of pericytes present in the
two sets of tumors (Fig. 2A, B). However, double staining for the
endothelial cell marker CD31 and the NG2-independent pericyte
marker platelet-derived growth factor beta-receptor (PDGFRβ)
revealed clear differences in the relationship between these two cell
populations. Compared to wild type hosts, NG2 null hosts exhibited an
increased number of pericytes lacking physical association with
CD31-positive endothelial tubes (Fig. 2A, C), suggesting a role for NG2
in mediating pericyte/endothelial cell interaction. Moreover, there
was a difference in the extent of pericyte coverage of endothelial
tubes in the two sets of tumors. Since CD31 and PDGFRβ are present
on distinct cell populations, they cannot overlap with each other in a
single optical section. However, because pericytes form an intricate
ensheathment of endothelial cells, the two labels appear to overlap
when viewed in 3-dimensional space. Analysis of z-stacks of confocal
images (Fig. 2A) therefore allowed us to quantify the extent to which
PDGFRβ labeling overlapped with CD31 labeling. The percentage of
the CD31 area with pericyte ensheathment was reduced two-fold in
tumor vessels in the NG2 null mouse (Fig. 2D). Very similar reductions
in pericyte ensheathment were seen when endosialin antibodies
(MacFadyen et al., 2007; Simonavicius et al., 2008) were used to label
pericytes (data not shown), verifying that the result is independent of
the choice of marker. Although the magnitude of investment was
lower, this difference in the pericyte ensheathment of endothelial
cells in wild type and NG2 null mice was also detectable in day
5 tumors, representing an intermediate stage of vessel development
during which pericytes are ﬁrst becoming evident (Fig. 2D).
Fig. 1. CT2A, B16F10, and B16F10/NG2 tumors in wild type and NG2 null mouse brain. Tumor sizes were measured in wild type and NG2 null mice that had been injected in the
corpus callosum with 1×104 CT2A, B16F10/NG2, or B16F10 cells. (A) Nine wild type and nine NG2 null mice were injected with CT2A cells and analyzed for tumor size at 26 days
post-injection. On average, CT2A tumors in NG2 null mice are 7-fold smaller than in wild type mice. (B) Seven wild type and seven NG2 null mice were injected with B16F10/NG2
cells and analyzed for tumor size at 11 days post-injection. The average tumor size was 10-fold smaller in NG2 null mice. (C) Fivemice in each groupwere analyzed at days 3, 5, 7, 11,
and 17 after injection of B16F10 cells. Average tumor sizes are plotted versus days post-injection. The inset panel shows the ﬁrst week after tumor initiation on an expanded scale,
revealing that tumors in wild type and NG2 null mice begin to diverge in size between 3 and 7 days post-injection. (D) Fifteen mice in each group were analyzed at 17 days after
injection of B16F10 cells. B16F10 tumors in NG2 null mice are at least 3-fold smaller than in wild type mice. Dashed lines show average tumor sizes. *Pb0.001. (E) Double
immunostaining for NG2 (green) and CD31 (red) shows that in both B16F10 and B16F10/NG2 tumors, NG2 is expressed by pericytes associated with CD31-positive endothelial cells.
Apart from the vasculature, NG2 is also strongly expressed by B16F10/NG2 tumor cells, but is absent from B16F10 tumor cells. Bar=100 μm.
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The interaction between pericytes and endothelial cells has
profound consequences for the maturation and function of both of
these cell types (Bergers and Song, 2005; Betsholtz et al., 2005;
Gaengel et al., 2009). For example, the reduced pericyte ensheath-
ment of endothelial cells observed in tumor vessels in NG2 null
mice results in a pronounced decrease in pericyte maturation.
This conclusion is based on quantiﬁcation of pericyte expression of
α-smooth muscle actin (αSMA), a marker that is largely absentfrom nascent murine pericytes but which is up-regulated as these
cells mature (Ozerdem et al., 2001; 2002; Song et al., 2005; Hamzah
et al., 2008). Double-labeling for PDGFRβ and αSMA (Fig. 2E) shows
that a portion of the PDGFRβ-positive pericytes in wild type tumor
vessels have begun to express αSMA after 7 days of tumor
development. In contrast, very little αSMA expression is seen in
PDGFRβ-positive pericytes in NG2 null tumor vessels at this time
point. Quantiﬁcation of the dual expression of these two markers
reveals a ten-fold decrease in αSMA expression by NG2 null pericytes
(Fig. 2F).
Fig. 2. Pericyte investment of tumor blood vessels and pericyte maturation. (A) To assess pericyte investment of blood vessels, sections of B16F10 tumor-bearing wild type (wt) and
NG2 null (ko) brains at 7 days post-injection were double-stained for CD31 and PDGFRβ. Confocal z-stacks of images were processed by image analysis to quantify several aspects of
the relationship between endothelial cells (red) and pericytes (green). Bar=100 μm. Data in panels B–D are derived from 4 independent tumors of each genotype, sampling 4 ﬁelds
from 3 sections in each tumor (12 ﬁelds×4 tumors). (B) Quantiﬁcation of green pixels allowed a comparison of the total number of pericytes per ﬁeld. (C) The extent to which
pericytes were not associated with endothelial tubes (detached pericytes) was assessed by quantifying the percentage of green pixels not in physical contact with red pixels. (D) The
extent of pericyte ensheathment of endothelial cells was determined by quantifying the percentage of red pixels that were covered by green pixels. These values were determined
both at day 5 and day 7 of tumor growth, revealing a deﬁcit in the NG2 null mouse at both days. *Pb0.01. (E) To evaluate pericyte maturation in tumor blood vessels, sections of 7-day
tumors were stained for CD31 to visualize blood vessels (not shown), and for PDGFRβ (green) and αSMA (red) to identify nascent and maturing pericytes, respectively. (F) Data in
panel F are derived from 4 independent tumors for each genotype, sampling 4 ﬁelds from 3 sections in each tumor. Confocal z-stacks of images were processed by image analysis to
quantify the extent to which the PDGFRβ label is coincident with αSMA. Bar=100 μm. *Pb0.0003.
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The effect of pericyte/endothelial cell interactiononendothelial cells
is reﬂected, in part, by deposition of the subendothelial basement
membrane, a critical step in vessel maturation. Although production of
the major extracellular matrix elements involved in basement mem-
brane assembly has been largely attributed to the vascular endothelium,
it is clear that pericyte investment of endothelial cells is required for
effective basal lamina deposition (Kalluri, 2003; Davis and Senger,Fig. 3. Basal lamina deposition in tumor blood vessels. (A) To evaluate basal lamina assem
CD31 (red) and collagen IV (green). Bar=100 μm. (B) Data in panel B are derived from 3 in
Both day 5 and day 7 tumors were analyzed. Confocal z-stacks of images were processed b
CD31 labeling. Basal lamina deposition is reduced in the NG2 null mouse at both time p
evaluated in wild type (wt), NG2 null (NG2 ko), and collagen VI null (coll VI ko)mice by dou
are derived from 3 tumors for each genotype, sampling 4 ﬁelds from 3 sections in each
percentage of CD31 pixels covered by collagen VI pixels. *Pb0.03. ND, not detectable. (E)
type, NG2 null, and collagen VI null mice. **Pb0.007 ***Pb0.002.2005). We have used an antibody against collagen IV, the predominant
collagen species present in vascular basement membranes, to assess
basal lamina deposition associated with tumor vessels in specimens at
the 7-day time point. This analysis demonstrated a large decrease in
collagen IV deposition associated with tumor vessels in NG2 null hosts
(Fig. 3A). Image analysis of the overlap between collagen IV labeling and
CD31 labeling revealed a 4-fold decrease in collagen IV deposition in the
absenceofNG2 (Fig. 3B). Evenat5 days,whenpericyteensheathment of
endothelial cells is in its early stages, a deﬁciency in collagen IV-positivebly associated with blood vessels, sections of 7-day tumors were double-stained for
dependent tumors for each genotype, sampling 4 ﬁelds from 3 sections in each tumor.
y image analysis to quantify the extent to which collagen IV labeling overlapped with
oints. *Pb0.002. (C) Association of collagen VI with 7-day tumor blood vessels was
ble-staining for CD31 (red) and collagen VI (green). Bar=100 μm. (D) Data in panel D
tumor. Image analysis of z-stacks of confocal images allowed determination of the
Assembly of collagen IV-positive basal lamina was compared in tumor vessels in wild
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tumors (Fig. 3B), probably as a result of reduced pericyte/endothelial
cell interaction.
The effect of NG2 on collagen IV deposition might be an indirect
one in which the proteoglycan is necessary for mediating the
pericyte/endothelial cell interaction that promotes basal lamina
deposition (Davis and Senger, 2005). We have shown that NG2-
dependent activation of β1 integrin signaling in endothelial cells
(Fukushi et al., 2004) provides the basis for this pericyte/endothelial
cell interaction. In addition, NG2 might also have a more direct role in
mediating collagen IV deposition. A possible mechanism for this
scenario is suggested by the fact that NG2 is a cell surface ligand for
collagen VI (Stallcup and Huang, 2008). In turn, collagen VI has been
demonstrated as a binding partner for collagen IV (Kuo et al., 1997).
Thus the absence of NG2 could result in decreased collagen VI
deposition, leading to loss of anchorage for collagen IV. Analysis of
B16F10 tumors in wild type and NG2 null mice indeed reveals a large
decrease in vascular collagen VI deposition in the null mice (Fig. 3C).
In the absence of NG2, collagen VI deposition relative to CD31 labeling
is reduced by almost 3-fold (Fig. 3D). Further evidence for the
importance of collagen VI deposition is provided by examination of
B16F10 tumors implanted in collagen VI null mice. If collagen VI
anchorage to NG2 is necessary for collagen IV deposition, then we
should also ﬁnd reduced deposition of collagen IV in B16F10 tumor
vessels in the collagen VI null mouse. As predicted, collagen IV
deposition is reduced in the collagen VI null mouse to an even larger
degree (4-fold) than in the NG2 null mouse (Fig. 3E). These
observations are consistent with a model in which NG2 is needed
for collagen VI anchorage, with collagen VI in turn providing a scaffold
for assembly of the collagen IV-containing basal lamina.Effects of host NG2 ablation on vessel function
The observed deﬁcits in pericyte coverage, pericyte maturation,
and basal lamina deposition in the tumor vessels of the NG2 null
mouse might be expected to have negative effects on vessel function.
To investigate this possibility, we used perfusion with FITC-LEA lectin
to examine vessel patency, and perfusion with FITC-dextran to
examine vessel leakiness. As stated above, we did not observe aFig. 4. Patency of tumor vessels. (A) Patency of 7-day tumor vessels was determined follo
unbound lectin. Sections were then stained for VEGFR-2 (red) to allow comparison of the tot
positive vessels without LEA lectin labeling. Bar=100 μm. (B) Data in panel B are derived
tumor. Image analysis of z-stacks of confocal images allowed determination of the percentadifference in the number of CD31-positive vessels between tumors
growing in wild type and NG2 null mice. However, intravenous
injection of FITC-LEA lectin, followed by saline perfusion to remove
lectin that was not bound to endothelial cells, reveals that 7 day
tumors in NG2 null mice have decreased numbers of VEGFR2-positive
vessels that are perfused by the circulation (Fig. 4A). Whereas almost
all tumor vessels are patent in wild type mice, only 50% of the tumor
vessels are patent in NG2 null mice (Fig. 4B).
In addition, intravenous injection of FITC-dextran (250 kDa)
shows that patent tumor vessels in NG2 null hosts are considerably
leakier at 7 days than tumor vessels in wild type hosts (Fig. 5A, lower
panels). Quantiﬁcation of the percentage of FITC-dextran located
external to CD31-positive vessels reveals a 4-fold increase in tumor
vessel leakiness in the NG2 null mouse (Fig. 5B, right panel).
Interestingly, after 3 days of tumor development, vessels in both
wild type and NG2 null hosts exhibit a high level of leakage (Fig. 5A,
top panels and Fig. 5B, left panel; note the contrast in leakage between
tumor vessels and vessels outside the tumor). This is likely
attributable to the fact that pericyte investment of endothelial tubes
in the tumors is absent at day 3 (Fig. 5C), affecting vessel permeability
in both sets of hosts. At day 5, even though pericyte/endothelial cell
interaction in wild type mice is superior to that in NG2 null mice
(Fig. 2D), pericyte ensheathment is nevertheless at an early stage, so
that vessels are still leaky in both sets of tumor vessels (data not
shown). The development of an effective pericyte investment and
basal lamina in wild type hosts between days 3 and 7 may be the
primary reason why tumor growth in these animals diverges from
tumor growth in NG2 null animals during this time period.Effect of host NG2 ablation on tumor hypoxia
To further compare tumor vessel functionality in wild type and
NG2 null mice, we injected a pimonidazole hypoxia probe, followed
by immunocytochemistry to quantify the extent of local hypoxia. At
3 days of tumor development, tissue hypoxia is low in both wild type
and NG2 null mice, despite the leakiness of tumor vessels in both
cases (Fig. 6A, B). The extremely small size of these tumorsmay allow
them access to gases and nutrients even in the absence of an efﬁcient
vasculature. After 7 days of tumor growth, however, high levels ofwing intravenous injection of FITC-LEA lectin (green), followed by perfusion to clear
al number of blood vessels with the number of patent vessels. Arrows denote VEGFR-2-
from 4 independent tumors for each genotype, sampling 4 ﬁelds in 3 sections in each
ge of VEGFR-2 pixels covered by LEA lectin pixels. *Pb0.001.
Fig. 5. Leakiness of tumor vessels. (A) Leakiness of tumor vessels at 3 (top panels) and 7 (lower panels) days post-injection (dpi) was visualized by intravenous injection of
FITC-dextran (green) followed by a 10-min circulation period and tissue ﬁxation. Sections were stained for CD31 (red) to deﬁne blood vessel boundaries. Dashed lines show the
brain–tumor boundaries at 3 dpi. Bar=100 μm. z-stacks of confocal images were processed by image analysis to quantify FITC-dextran pixels lying external to CD31-positive
vessels. (B) Data in panel B are derived from 3 independent tumors for each genotype, sampling 4 ﬁelds in 3 sections from each tumor. The extravascular FITC-dextran area
is expressed as the percentage of the total tumor area at 3 dpi (left panel) and 7 dpi (right panel). *Pb0.001. (C) Pericyte investment of tumor vessels in wild type mice at 3 days
post-injection was evaluated by double-staining for CD31 (red) and PDGFRβ (blue) in sections from FITC-dextran-perfused (green) tumors at 3 dpi. Dashed lines mark brain–
tumor boundaries. Bar=100 μm.
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tumors in wild type mice exhibit 20-fold lower levels of hypoxia
(Fig. 6C, D).
Discussion
Since blood vessels are critical elements of the tumor micro-
environment, mechanisms responsible for the recruitment and devel-
opment of vascular components are of key importance to our
understanding of tumor progression and to our attempts to manip-
ulate this process. Of the two primary vascular cell types, vascular
endothelial cells have traditionally received the most attention in
studies of blood vessel development. However, it is clear that
perivascular cells (pericytes) also are required for establishment
and maintenance of a functional vasculature (Betsholtz et al., 2005;
Bergers and Song, 2005; Hall, 2006; Gaengel et al., 2009). In addition
to stabilization of endothelial tubes, pericytes play much earlier roles
in neovascularization than previously suspected (Schlingemann et al.,
1990;1996; Nehls et al., 1992; Wesseling et al., 1995; Redmer et al.,
2001; Ozerdem et al., 2001; 2002; Ozerdem and Stallcup, 2003; Song
et al., 2005; Virgintino et al., 2007). Recognition of this important,
early role of pericytes in blood vessel development is due in part to the
use of markers such as PDGFRβ and NG2 proteoglycan that permit
identiﬁcation of perivascular cells at early time points in their
development. By contrast, the use of markers such as αSMA oftenfails to reveal the early involvement of pericytes in microvessel
development, due to the fact thatαSMA is expressed bymature rather
than nascent pericytes.
While the importance of PDGFRβ signaling in pericyte recruitment
and development has been well documented (Lindahl et al., 1997;
Lindahl and Betsholtz, 1998; Hellstrom et al., 1999; 2001; Enge et al.,
2002), the role of NG2 in pericyte biology is just beginning to emerge.
In a number of different cell types, NG2 has been shown to promote
proliferation and motility (Burg et al., 1997, 1998; Grako and Stallcup,
1995; Grako et al., 1999; Makagiansar et al., 2004; 2007; Kadoya et al.,
2008; Kucharova and Stallcup, 2010), suggesting that genetic ablation
of NG2 might have a negative effect on pericyte recruitment.
Recruitment deﬁcits resulting from NG2 ablation have been docu-
mented most clearly in models of retinal neovascularization in
response to ischemia, and corneal neovascularization in response to
FGF2 (Ozerdem and Stallcup, 2004). In both cases, pericyte recruit-
ment is severely compromised in the NG2 null mouse, resulting in
reduced establishment of new blood vessels. Other studies from our
group have provided indications that NG2 not only affects pericyte
recruitment, but also is able to mediate pericyte/endothelial cell
interaction. NG2 interacts physically with β1 integrins and can
promote β1 integrin activation in both cis and trans settings, i.e.
with the two molecules expressed either on the same cell or on
neighboring cells (Fukushi et al., 2004; Makagiansar et al., 2004, 2007;
Chekenya et al., 2008). Thus, in the case of pericyte/endothelial cell
Fig. 6. Levels of tissue hypoxia in tumors. Tissue sections were prepared from animals that had been injected with pimonidazole hypoxia probe at 3 (A) and 7 days (C) of tumor
development. Sections were double-stained for pimonidazole (green) and CD31 (red). Data in panels B and D were derived from 3 independent tumors for each genotype, sampling
4 ﬁelds in 3 sections from each tumor. Hypoxia levels at 3 (B) and 7 (D) dpi were determined as the percentage of total tumor area covered by pimonidazole pixels. Dashed lines
illustrate brain–tumor boundaries. *P=0.192, **Pb0.0001. Bar=100 μm.
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signaling in endothelial cells, promoting endothelial cell recruitment
and morphogenesis (Fukushi et al., 2004). Ablation of NG2 would
therefore be expected to have a negative effect on pericyte/
endothelial cell interaction.
The fact that genetic ablation of NG2 causes reduced neovascu-
larization in both corneal and retinal models (Ozerdem and
Stallcup, 2004) suggests that tumor vascularization and tumor
growth might also be reduced in the NG2 null mouse. In fact, two
brief reports have demonstrated reduced microvascular densities in
transplanted prostate (Ozerdem, 2006a) and uveal melanoma
tumors (Ozerdem, 2006b) grown in NG2 null mice. In our current
work, we have examined this question in more depth using en-
graftment of NG2-negative and NG2-positive B16F10 melanoma
cells, and also NG2-positive CT2A astrocytoma cells into the subcortical
white matter of wild type and NG2 null mouse brains to evaluate the
importance of NG2 in the microenvironment of brain tumors. While
studying the growthof human tumor cell lines in immune compromised
hosts remains an option for the future, evaluating the progression of the
C57Bl/6 tumors in syngeneic, immune competent recipients permits us
to examine all aspects of the tumor microenvironment, including
elements of the host immune/inﬂammatory response.Our results show that tumor progression by both astrocytoma cells
(CT2A) and melanoma cells (B16F10 and B16F10/NG2) is greatly
retarded in NG2 null hosts. In the case of CT2A and B16F10/NG2
tumors, mechanistic interpretations of these phenomena are compli-
cated by the presence of NG2 not only in the tumor stroma, but also on
the tumor cells themselves, possibly contributing to tumor cell
proliferation and invasion. However, since NG2 is not expressed by
the tumor cells in the B16F10 model, stromal elements must be
responsible for these effects of NG2 ablation on tumor progression. In
addition to its expression in the vasculature, NG2 can also be found on
other components of the tumor microenvironment. In the context of
the central nervous system, NG2 is expressed by oligodendrocyte
progenitors and by macrophages/microglia (Stallcup and Huang,
2008), both of which can contribute to brain tumor progression.
Leaving these latter two cell types for future investigation, we have
focused our initial attention on pericytes in the B16F10 tumor blood
vessels. In the NG2 null mouse, the extent of pericyte ensheathment of
the tumor vascular endothelium is reduced two-fold compared to that
seen in the wild type mouse. This is true during the early stages of
pericyte/endothelial cell interaction (day 5) aswell as inmoremature
vessels (day 7), suggesting that the primary effect of NG2 ablation in
this model is on the quality of the interaction that occurs between
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that NG2 ablation should negatively affect pericyte-dependent
activation of β1 integrin signaling in endothelial cells, resulting in
loss of crosstalk between the two cell populations (Fukushi et al.,
2004).
The relatively modest two-fold decrease in pericyte ensheathment
of endothelial cells observed in the NG2 null mouse brain has rather
dramatic effects on vessel maturation and function. The developmen-
tal programs of both pericytes and endothelial cells are affected by the
interaction between the two cell types, and maturation of both cell
types is negatively impacted by the decreased pericyte ensheathment
of endothelial cells seen in the NG2 null mouse. In the case of
pericytes, we ﬁnd that expression of the maturation marker αSMA is
drastically curtailed due to reduced pericyte/endothelial cell interac-
tion in the absence of NG2. In the case of endothelial cells, impaired
interaction between endothelial cells and NG2 null pericytes leads to
severely compromised ability of the endothelial cells to assemble the
vascular basal lamina (as judged by a 2 to 4-fold decrease in collagen
IV deposition at days 5 and 7, respectively). The deposition of this
subendothelial basement membrane is one of the most important
consequences of the pericyte/endothelial cell collaboration, since it
serves to stabilize the maturing vessel. In the B16F10 model at days 5
and 7, assembly of the collagen IV-positive basal lamina appears to
proceed in parallel with pericyte ensheathment of endothelial cells. In
addition to its β1 integrin-dependent role in pericyte/endothelial cell
crosstalk, (Fukushi et al., 2004), NG2 also appears capable of exerting
a more direct effect on basal lamina deposition by acting as a cell
surface receptor for collagen VI (Stallcup et al., 1990; Nishiyama and
Stallcup, 1993; Burg et al., 1996, 1997; Tillet et al., 1997, 2002).
Collagen VI serves as a linker between cell surface receptors (such as
NG2) and other ﬁbrillar collagen species, including collagen IV (Kuo
et al., 1997), involved in assembly of extracellular matrices and
basement membranes. Ablation of NG2 thus reduces the anchorage of
collagen VI to the cell surface, which in turn eliminates a nucleation
point for assembly of the collagen IV-containing basal lamina.
Functional consequences of these deﬁcits in vessel maturation in
the NG2 null mouse include decreased patency of B16F10 tumor
vessels, as judged by perfusion with FITC-LEA lectin, and increased
leakiness of vessels that are perfused by the circulation, as detected by
vascular loss of intravenously injected FITC-dextran. The decrease in
tumor vessel leakiness seen in wild typemice between days 3 and 7 of
tumor development coincides with the development of pericyte
ensheathment. At 3 days of tumor development, vessels have not yet
acquired a pericyte investment, and at 5 days ensheathment is
incomplete. At these time points, vessels are permeable to FITC-
dextran in both wild type and NG2 null mice. However, by 7 days,
pericyte-ensheathed tumor vessels in wild type mice are dramatically
less leaky, while signiﬁcant FITC-dextran leakage is still seen in NG2
null mice. Probably as a result of both poor vessel patency and
increased vessel leakiness, tumors in NG2 null mice exhibit 20-fold
higher levels of hypoxia than tumors in wild type mice. In NG2 null
mice, the failure to develop an effective pericyte investment, the
continuing vessel leakiness, and the development of high levels of
tissue hypoxia all occur during the same time period (days 3–7) when
tumor growth in these animals diverges from the more rapid growth
observed in wild type mice. These observations suggest a causal
relationship between vessel performance and tumor progression.
These effects of NG2 ablation are not restricted to tumors growing in
the brain. In addition to reduced vascularization of prostate
(subcutaneous) and uveal melanoma (cornea) xenografts in the
NG2 null mouse (Ozerdem, 2006a,b), work in progress in our
laboratory shows that NG2 ablation in the context of the MMTV-
PyMT transgenic mouse model (Lin et al., 2003) greatly slows
mammary tumor progression. Since NG2 is not expressed by
mammary tumor cells in this model, the effects of NG2 ablation
must come from the tumor stroma. Using the same methodologydescribed in this report, we detect deﬁcits in pericyte/endothelial cell
interaction in mammary tumor vessels of the NG2 null mouse, leading
to reduced basal lamina deposition and to high levels of tumor
hypoxia (our unpublished data).
The consequences of NG2 ablation on tumor vascularization are in
dramatic contrast to the results of knocking out another pericyte-
speciﬁc marker, regulator of G-protein signaling 5 (Rgs5). Compared
to tumor vessels in wild type mice, tumor vessels in Rgs5-deﬁcient
mice exhibit a normalized morphology and reduced leakiness,
resulting in decreased tissue hypoxia and enhanced tumor growth
(Hamzah et al., 2008). These contrasting results undoubtedly reﬂect
the different roles that NG2 and Rgs5 play in pericyte biology,
although both of these roles remain incompletely understood. Rgs5
appears to inhibit vessel maturation, so that its ablation allows
maturation to occur. On the other hand, we show here that NG2 is
important for pericyte/endothelial cell interaction and vessel matu-
ration, so that its ablation interferes with the maturation process.
Since pericyte/endothelial cell interactions are fundamental to all
types of vascularization models, these ﬁndings have relevance that
extends far beyond the speciﬁc example of tumor vascularization
studied in the current work.
In future investigations, we will seek additional details concerning
the mechanisms underlying this vascular role of NG2. In addition, we
will further examine the important role of NG2 in the proliferative and
invasive properties of the tumor cells themselves. Previous work has
indicated that tumor cell NG2 has important effects on both
melanoma and glioma progression (Burg et al., 1998; Chekenya
et al., 2008). However, these studies were not designed to dissect the
respective contributions of tumor cell NG2 and stromal NG2. The very
large growth discrepancy in wild type versus NG2 null mice seen in
our current study with NG2-positive tumor cells (B16F10/NG2 and
CT2A) suggest that there might be a synergistic effect between tumor
cell and stromal NG2. Orthotopic transplantations in NG2 null mice
using the B16F10 and B16F10/NG2 cells will be able to identify the
speciﬁc effects of tumor cell NG2 on tumor progression. The
multifunctional nature of NG2 and its expression by both tumor and
stromal cell types make the proteoglycan an intriguing target for
cancer therapy (Campoli et al., 2004; Maciag et al., 2008; Chekenya
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